

February 11, 2026



Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

*Self-Sustaining **Fusion® 800 Series** Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments*

NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology. This self-sustaining cryogenic freezer eliminates the need for a continuous liquid nitrogen (LN₂) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designed for space-constrained environments.



Recognized with the ISBER Outstanding New Product Award, MVE's Fusion technology transforms cryogenic storage. The new Fusion 800 builds on this innovative platform, offering the same trusted performance and energy efficiency in a lab-sized design. At just 32 inches wide, it fits through standard doorways for easy installation without costly facility modifications.

"The Fusion 800 is a major evolution and a step forward into the future," said Mike Duich, President and CEO of MVE Biological Solutions. "Fusion 800 delivers the storage density, flexibility, and operational freedom our customers demand without the infrastructure burden of traditional cryogenic systems. This product opens the door for more facilities to safely adopt true cryogenic storage."

"Truly transformative products are rare in this industry, but the MVE Fusion 800 is one of them," said Jerrell Shelton, CEO of Cryoport. "It solves a longstanding challenge in cryogenic storage by protecting critical biological materials and life-saving therapies without the space and infrastructure requirements of legacy cryogenic storage systems. We believe

the Fusion 800 is on a path to becoming the new standard in research facilities and hospital pharmacies worldwide."

Ideal for medical research facilities, clinical development operations, hospital pharmacies and clinics, biorepositories, and blood and tissue banks, etc., the Fusion 800 offers versatile storage options for vials, blood bags, cassettes, etc., maintaining steady state temperatures at or below -150°C.

For more information on the MVE Fusion® 800 Series, visit: <https://mvebio.com/> or consult with an MVE distributor.

About Cryoport, Inc


[Cryoport, Inc.](https://cryoportinc.com/) (Nasdaq: CYRX), is a leading global provider of temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoport® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are **"Enabling the Future of Medicine™."**

Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

For more information, visit www.cryoportinc.com or follow via LinkedIn at <https://www.linkedin.com/company/cryoportinc> or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.

Forward-Looking Statements

Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

 View original content to download multimedia <https://www.prnewswire.com/news-releases/cryoport-mve-biological-solutions-introduces-new-fusion-800-series-302684810.html>

SOURCE Cryoport, Inc.